ERBB2 and neoplasm: Concurrent administration of a PD-1 inhibitor and trastuzumab enhances the HER2-specific T-cell responses [25, 34], and facilitates the development of immunological memory for effective tumor eradication, thereby safeguarding against tumor relapse [37].